Varegacestat’s pivotal study reads out imminently.
ApexOnco Front Page
Recent articles
The pivotal Harmoni-GI3 study has started enrolling patients.
BNT329 enters the clinic, as do four other new ADCs.
Four more failed tiragolumab trials, including Imbrave-152, will feature.
ALE.P03 is the biotech's third anti-Claudin1, and its second ADC.
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
The Chinese group will soon start a pivotal trial of its ADC ruza-can in first-line NSCLC.
While InxMed, Takara and L&L have phase 3 plans in lung cancer and beyond.
